Asahi Glass to buy CMC Biologics | Chemical & Engineering News
Volume 95 Issue 1 | p. 13 | Concentrates
Issue Date: January 2, 2017

Asahi Glass to buy CMC Biologics

Department: Business
Keywords: biologics, contract manufacturing, Asahi Glass

Japan’s Asahi Glass has agreed to acquire CMC Biologics, a contract manufacturer of biologic drugs, for $510 million. The purchase continues the glass and chemical maker’s push into biologic drug manufacturing. In August, Asahi announced plans to buy the German contract manufacturer Biomeva. Private equity-owned CMC operates plants in Copenhagen, Seattle, and Berkeley, Calif., that produce biologic drug ingredients in mammalian and microbial hosts. It has about 530 employees.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment